SMID Equity Strategy "Simply SMID (EU): The discount wears Prada" Chedda

Research evidence excerpt

SMID Equity Strategy "Simply SMID (EU): The discount wears Prada" Chedda

Global Research

9 June 2026ab

SMID Equity Strategy Equity Strategy

Europe including UKSimply SMID (EU): The discount wears Prada

Sutanya Chedda

Strategist

Repair, but not release sutanya.chedda@ubs.com

+44-20-7567 8155

The SMID story has improved, but it has not unlocked. The tape is less hostile: revision

breadth is closer to neutral, c.70% of SMIDs still trade below their own 10-year Gerry Fowler

Strategistvaluation average, quality SMIDs retain a material rerating discount and dispersion

gerry.fowler@ubs.com

remains high enough for alpha. But a genuine broadening would show up in domestic +44-20-7567 5490

cyclicals, equal-weight participation, M&A activity, cash conversion and SMID beta at the

same time. It does not. The evidence is more precise than bullish: SMIDs are repairing,

but the market is still rationing capital to companies that can fund themselves, convert

accounting recovery into cash and carry thematic demand.

Regime: Easier money, incomplete transmission

The macro backdrop is more permissive, but permissive is not the same as transmissive. REVS

Financial conditions have eased, yet SMID beta has not responded. Breadth is better, but

Equities move based on:

not broad; only IT clears the combined breadth and fundability test, while domestic

exposure still fails to behave like the natural SMID recovery trade. This is why SMIDs Regime,

should not be treated as a simple asset-class rotation. They remain a financing regime

instrument, more sensitive to funding access, liquidity, refinancing walls and investor Earnings,

willingness to underwrite duration. The YTD squeeze in low-fundability laggards is

tactical. The structural signal is unchanged: self-funding still owns the regime.